vs

Side-by-side financial comparison of Black Stone Minerals, L.P. (BSM) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Black Stone Minerals, L.P. is the larger business by last-quarter revenue ($95.2M vs $74.7M, roughly 1.3× Health Catalyst, Inc.). Black Stone Minerals, L.P. runs the higher net margin — 75.9% vs -121.9%, a 197.8% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -8.7%). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -9.7%).

Black Stone Minerals, L.P., or Black Stone Minerals, is a Houston, Texas-based oil and natural gas corporation.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

BSM vs HCAT — Head-to-Head

Bigger by revenue
BSM
BSM
1.3× larger
BSM
$95.2M
$74.7M
HCAT
Growing faster (revenue YoY)
HCAT
HCAT
+2.5% gap
HCAT
-6.2%
-8.7%
BSM
Higher net margin
BSM
BSM
197.8% more per $
BSM
75.9%
-121.9%
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-9.7%
BSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BSM
BSM
HCAT
HCAT
Revenue
$95.2M
$74.7M
Net Profit
$72.2M
$-91.0M
Gross Margin
Operating Margin
78.6%
-115.3%
Net Margin
75.9%
-121.9%
Revenue YoY
-8.7%
-6.2%
Net Profit YoY
55.8%
-340.3%
EPS (diluted)
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BSM
BSM
HCAT
HCAT
Q4 25
$95.2M
$74.7M
Q3 25
$105.2M
$76.3M
Q2 25
$106.7M
$80.7M
Q1 25
$115.3M
$79.4M
Q4 24
$104.3M
$79.6M
Q3 24
$103.2M
$76.4M
Q2 24
$115.2M
$75.9M
Q1 24
$116.8M
$74.7M
Net Profit
BSM
BSM
HCAT
HCAT
Q4 25
$72.2M
$-91.0M
Q3 25
$91.7M
$-22.2M
Q2 25
$120.0M
$-41.0M
Q1 25
$15.9M
$-23.7M
Q4 24
$46.3M
$-20.7M
Q3 24
$92.7M
$-14.7M
Q2 24
$68.3M
$-13.5M
Q1 24
$63.9M
$-20.6M
Gross Margin
BSM
BSM
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
BSM
BSM
HCAT
HCAT
Q4 25
78.6%
-115.3%
Q3 25
89.5%
-22.9%
Q2 25
-46.0%
Q1 25
14.9%
-25.4%
Q4 24
45.6%
-22.0%
Q3 24
90.2%
-17.9%
Q2 24
59.5%
-20.8%
Q1 24
54.8%
-30.5%
Net Margin
BSM
BSM
HCAT
HCAT
Q4 25
75.9%
-121.9%
Q3 25
87.2%
-29.1%
Q2 25
112.5%
-50.8%
Q1 25
13.8%
-29.9%
Q4 24
44.4%
-26.0%
Q3 24
89.9%
-19.3%
Q2 24
59.3%
-17.8%
Q1 24
54.7%
-27.6%
EPS (diluted)
BSM
BSM
HCAT
HCAT
Q4 25
$-1.29
Q3 25
$-0.32
Q2 25
$-0.59
Q1 25
$-0.35
Q4 24
$-0.33
Q3 24
$-0.24
Q2 24
$-0.23
Q1 24
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BSM
BSM
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$1.5M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
Total Assets
$1.3B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BSM
BSM
HCAT
HCAT
Q4 25
$1.5M
$95.7M
Q3 25
$2.9M
$91.5M
Q2 25
$2.5M
$97.3M
Q1 25
$2.4M
$342.0M
Q4 24
$2.5M
$392.0M
Q3 24
$21.0M
$387.3M
Q2 24
$26.7M
$308.3M
Q1 24
$40.5M
$327.8M
Total Debt
BSM
BSM
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
BSM
BSM
HCAT
HCAT
Q4 25
$245.8M
Q3 25
$331.9M
Q2 25
$347.5M
Q1 25
$376.8M
Q4 24
$365.2M
Q3 24
$355.0M
Q2 24
$357.0M
Q1 24
$357.2M
Total Assets
BSM
BSM
HCAT
HCAT
Q4 25
$1.3B
$502.6M
Q3 25
$1.3B
$587.1M
Q2 25
$1.3B
$616.2M
Q1 25
$1.2B
$891.5M
Q4 24
$1.2B
$858.9M
Q3 24
$1.2B
$813.0M
Q2 24
$1.2B
$691.7M
Q1 24
$1.2B
$695.1M
Debt / Equity
BSM
BSM
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BSM
BSM
HCAT
HCAT
Operating Cash FlowLast quarter
$65.1M
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BSM
BSM
HCAT
HCAT
Q4 25
$65.1M
$9.9M
Q3 25
$99.8M
$-464.0K
Q2 25
$80.5M
$-9.0M
Q1 25
$64.8M
$280.0K
Q4 24
$91.0M
$-3.5M
Q3 24
$93.2M
$6.2M
Q2 24
$100.4M
$1.6M
Q1 24
$104.5M
$10.3M
Free Cash Flow
BSM
BSM
HCAT
HCAT
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
Q1 24
$10.1M
FCF Margin
BSM
BSM
HCAT
HCAT
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Q1 24
13.5%
Capex Intensity
BSM
BSM
HCAT
HCAT
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
0.5%
Q3 24
0.9%
Q2 24
0.4%
Q1 24
0.3%
Cash Conversion
BSM
BSM
HCAT
HCAT
Q4 25
0.90×
Q3 25
1.09×
Q2 25
0.67×
Q1 25
4.07×
Q4 24
1.96×
Q3 24
1.01×
Q2 24
1.47×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BSM
BSM

Oil Reserves$46.4M49%
Natural Gas Reserves$44.1M46%
Real Estate$4.7M5%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons